3-乙基六氢-1-甲基-2H-氮杂卓-2-酮 | 59891-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: 3-乙基六氢-1-甲基-2H-氮杂卓-2-酮
• 中文别名: 分散蛋黄227
• 英文名称: 3-ethylhexahydro-1-methyl-<1H>azepin-2-one
• 英文别名: 3-Ethyl-N-methylhexahydroazepin-2-on；3-ethyl-1-methyl-azepan-2-one；3-ethylhexahydro-1-methyl-2H-azepin-2-one；3-ethyl-1-methylazepan-2-one
• CAS: 59891-41-7
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: TWJZVJYUCAHEGB-UHFFFAOYSA-N

物化性质

• 沸点：
  110-111 °C(Press: 28 Torr)
• 密度：
  0.916±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-乙基六氢-1-甲基-2H-氮杂卓-2-酮 以78%的产率得到
  参考文献：
  名称：

  CUVIGNY T.; HULLOT P.; MULOT P.; LARCHEVEQUE M.; NORMANT H., CAN. J. CHEM., 1979, 57, NO 10, 1201-1205

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基己内酰胺 、 溴乙烷 在 lithium diisopropyl amide 作用下， 生成 3-乙基六氢-1-甲基-2H-氮杂卓-2-酮
  参考文献：
  名称：

  Bradley; Cavalla; Edington, European Journal of Medicinal Chemistry, 1980, vol. 15, # 4, p. 375 - 385

  摘要：

  DOI：

文献信息

• Hexahydroazepine, piperidine and pyrrolidine derivatives
  申请人：John Wyeth & Brother Limited

  公开号：US04197239A1

  公开（公告）日：1980-04-08

  The invention concerns novel 2-oxo-hexahydroazepine, -piperidine and -pyrrolidine of formula I ##STR1## where n is 2,3 or 4, R is hydrogen, lower alkyl or aryl(lower)alkyl and R.sup.1 is lower alkyl. The compounds may be aromatized and the aromatized compounds converted to 3,3-disubstituted-hexahydroazepine, -piperidine and -pyrrolidine compounds having pharmacological activity, particularly analgesic activity.

  这项发明涉及具有以下式I的新型2-氧代-六氢吡嗪、-哌啶和-吡咯啉化合物##STR1##其中n为2、3或4，R为氢、较低的烷基或芳基(较低)烷基，R.sup.1为较低的烷基。这些化合物可以芳构化，芳构化的化合物可以转化为具有药理活性的3,3-二取代-六氢吡嗪、-哌啶和-吡咯啉化合物，特别是镇痛活性。
• Process for preparing hexahydroazepine, piperidine and pyrrolidine
  申请人：John Wyeth & Brother Limited

  公开号：US04296029A1

  公开（公告）日：1981-10-20

  2-Oxo-hexahydroazepine, -piperidine or pyrrolidines of formula ##STR1## wherein n is 2,3 or 4, R is hydrogen, lower alkyl, aryl(lower)alkyl, loweralkenylmethyl or cycloalkylmethyl, R.sup.1 is hydrogen or lower alkyl and R.sup.2 is hydrogen, lower alkyl or aryl(lower)alkyl are prepared by a novel process involving reaction of an anion of a lactam of formula ##STR2## where R.sup.3 is lower alkyl, aryl(lower)alkyl, trialkyl-, triaryl- or triarylalkyl-silyl with a benzyne of formula ##STR3## where R.sup.4 is lower alkyl, aryl(lower)alkyl or trialkyl-, triaryl- or triarylalkyl-silyl. The products are useful as intermediates for preparing pharmacologically active 2-unsubstituted -hexahydroazepine, -piperidine and pyrrolidine derivatives.

  公式为##STR1##的2-氧代-己内酰胺，-哌啶或吡咯烷化合物，其中n为2、3或4，R为氢、低碳基、芳基（低）烷基、低烯基甲基或环烷基甲基，R.sup.1为氢或低碳基，R.sup.2为氢、低碳基或芳基（低）烷基，通过一种新颖的方法制备，其中包括将公式为##STR2##的内酰胺阴离子（其中R.sup.3为低碳基、芳基（低）烷基、三烷基、三芳基或三芳基烷基硅烷基）与公式为##STR3##的苯并环丙烯反应。所得产物可用作制备具有药理活性的2-未取代-己内酰胺，-哌啶和吡咯烷衍生物的中间体。
• Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production
  申请人：Olson E. Richard

  公开号：US20070027132A1

  公开（公告）日：2007-02-01

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式（I）的新型内酰胺，其制药组合物以及使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• Hexahydroazepine, piperidine and pyrrolidine derivatives and processes for making and using them
  申请人：JOHN WYETH & BROTHER LIMITED

  公开号：EP0003253A1

  公开（公告）日：1979-08-08

  2-Oxo-hexahydroazepine, -piperidine and -pyrrolidine derivatives of general formula (I) where n is 2, 3 or 4, R is hydrogen, lower alkyl or aryl(lower)alkyl and R' is hydrogen or lower alkyl are novel intermediates for their aromatised derivatives of formula (II) where n and R' are as defined above, R2 is hydrogen, lower alkyl or aryl(lower)alkyl and R3 is hydrogen, lower alkyl, aryl(lower)alkyl, lower alkenyl or lower alkynyl. The aromatised derivatives (of which those in which R' is hydrogen are novel) can be converted into 3,3-disubstituted- hexahydroazepine, -piperidine and -pyrrolidine derivatives having pharmacological activity, particularly analgesic activity.

  通式 (I) 的 2-氧代六氢氮杂卓、-哌啶和-吡咯烷衍生物 其中 n 为 2、3 或 4，R 为氢、低级烷基或芳基（低级）烷基，R'为氢或低级烷基，是通式（II）芳香化衍生物的新型中间体 其中 n 和 R' 如上定义，R2 是氢、低级烷基或芳基（低级）烷基，R3 是氢、低级烷基、芳基（低级）烷基、低级烯基或低级炔基。芳香化衍生物（其中 R' 为氢的衍生物为新型衍生物）可转化为具有药理活性，特别是镇痛活性的 3,3-二取代-六氢氮杂卓、-哌啶和-吡咯烷衍生物。
• Method of preparing 2-oxo- and 2-unsubstituted-hexahydroazepine derivatives
  申请人：JOHN WYETH & BROTHER LIMITED

  公开号：EP0021772A1

  公开（公告）日：1981-01-07

  2-Oxo-hexahydroazepines, -piperidines or -pyrrolidines of formula wherein n is 2,3 or 4, R is hydrogen, lower alkyl, aryl-(lower)alkyl, loweralkenylmethyl or cycloalkylmethyl, R' is hydrogen or lower alkyl and R2 is hydrogen, lower alkyl or aryl(lower)alkyl are prepared by a novel process involving reaction of an anion of a lactam of formula where R3 is lower alkyl, aryl(lower)alkyl or trialkyl-, triaryl- or triarylalkyl-silyl, lower alkenylmethyl or cycloalkylmethyl with a benzyne of formula where R4 is lower alkyl, aryl(lower)alkyl or trialkyl-, triaryl or triarylalkyl-silyl. The products are useful as intermediates for preparing pharmacologically active 2-unsubstituted -hexahydroazepine, -piperidine and -pyrrolidine derivatives of general formula (II) where R5 is lower alkyl and n, R and R2 are as defined above, by C-alkylating a compound of general formula (I), where R' is hydrogen, and reducing this compound.

  式中的 2-氧代六氢氮杂卓、-哌啶类或-吡咯烷类 式中 n 为 2、3 或 4，R 为氢、低级烷基、芳基（低级）烷基、低级烯基甲基或环烷基甲基，R'为氢或低级烷基，R2 为氢、低级烷基或芳基（低级）烷基。 式中 R3 为低级烷基、芳基（低级）烷基或三烷基、三芳基或三芳基烷基硅基、低级烯基甲基或环烷基甲基的阴离子与式中的苄基反应 其中 R4 为低级烷基、芳基（低级）烷基或三烷基、三芳基或三芳基烷基硅基。这些产物可作为中间体，用于制备具有药理活性的通式（II）的 2-未取代-六氢氮杂卓、-哌啶和-吡咯烷衍生物。 其中 R5 为低级烷基，n、R 和 R2 如上定义，通过将通式（I）化合物（其中 R' 为氢）C-烷基化并还原该化合物。